Outcomes With Combination Therapy


Continue Reading

“Kidney cancer is ahead because the combination treatments are well underway,” Dr Plimack said. The combination of immune checkpoint inhibition with other agents — including a second checkpoint inhibitor or targeted therapy — has become the next frontier in mRCC. Multiple phase 1 through 3 trials are underway to evaluate these combinations in the first or second line.

Some attempts at combination treatment resulted in disappointing outcomes. Temsirolimus plus interferon, for example, did not improve ORR, PFS, or OS compared with temsirolimus or interferon alone.3 Other combinations were not well-tolerated. “For the combination of VEGF inhibitors with immunotherapy, again, the early trials were not moved forward due to toxicities, but newer combinations, like with axitinib, seem to be tolerable and they are showing nice early results,” Dr Plimack said.

Combinations that include immune checkpoint inhibitors, however, are beginning to show promising outcomes. Results from the first phase 3 trial of combination immunotherapy were recently presented at the 2017 European Society for Medical Oncology (ESMO) Congress.4 In the CheckMate 214 trial, 1096 patients with previously untreated clear cell mRCC were randomly assigned to receive nivolumab plus ipilimumab or sunitinib for a minimum follow-up of 17.5 months. The confirmed ORR for patients with intermediate/poor risk disease was 41.6% compared with 26.5% with sunitinib, with 9.4% of patients showing a compete response. The duration of response was not reached compared with 14.82 months with sunitinib.

Related Articles

Though combination treatments may have greater efficacy, this comes with a greater risk of adverse events. “We know there are higher rates of autoimmune adverse events when we combine ipilimumab and nivolumab compared with a PD-1 inhibitor alone,” Dr Plimack said.

Though these responses may hint at the potential of a cure, Dr Plimack cautions that “these results are encouraging, but they are definitely early.”

Is Cure in the Future?

Dr Plimack noted that though uncommon, CRs are seen among patients with metastatic disease, but CRs seem to occur more often with immune checkpoint inhibitors. She highlighted, however, that “a prerequisite before we can talk about cure is going to be a treatment-free survival period. I don’t think we can call it cure if they are still on active treatment.”

Treatment-free remission, according to Dr Plimack, is “stopping treatment and following the patient with scans and watching their disease control, whether it is a CR or not.” Given that immune checkpoint inhibitors have only been available for 5 years and approved in mRCC for 2 years, it is too early to declare any patients cured. Dr Plimack said that, “in 10 years from now, we may be able to say cure or not.”

References

  1. Sabanathan D, Park JJ, Marquez M, Francisco L, Byrne N, Gurney H. Cure in advanced renal cell cancer: is it an achievable goal? Oncologist. 2017;22:1-8. doi: 10.1634/theoncologist.2017-0159
  2. Kidney cancer, version 2.2018. National Comprehensive Cancer Network website. http://www.nccn.org/professionals/physician_gls/pdf/kidney_blocks.pdf. Updated November 30, 2017. Accessed December 2017.
  3. Sanchez-Gastaldo A, Kempf E, Gonzalez Del Alba A, Duran I. Systematic treatment of renal cell cancer: a comprehensive review. Cancer Treat Rev. 2017;60:77-89. doi: 10.1016/j.ctrv.2017.08.010 0305-7372
  4. Escudier B, Tannir NM, McDermott DR, et al. CheckMate 214: Efficacy and safety of nivolumab 1 ipilimumab (N1I) v sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups. Oral presentation at: 2017 European Society for Medical Oncology (ESMO) Congress. Madrid, Spain; September 8-12, 2017. Abstract LBA5.